AREG, in turn, upregulates the glutamine transporter SLC1A5 and promotes the accumulation of glutamine-derived TCA cycle metabolites via the EGFR/PI3K/AKT/mTOR signaling pathway, thereby promoting lung cancer cell growth and proliferation (Figure 8). Here, MTOR is linked to lung carcinoma.